January 6, 2021 -- Kite, a Gilead company, and Oxford BioTherapeutics have entered into a research collaboration to evaluate five novel cell therapy targets for hematologic and solid tumor indications.
As part of the collaboration, Oxford will validate five novel oncology targets that were previously identified using the company's Oxford Genome Anatomy Project (OGAP) discovery platform and will generate antibodies against the targets. Kite and Gilead will have the exclusive right to develop and commercialize therapies based on these targets or antibodies.
Under the agreement, Oxford will receive an upfront payment of an undisclosed amount and will be eligible to receive additional payments based on the achievement of certain discovery, clinical, and regulatory milestones, as well as royalties on future potential sales.
Copyright © 2021 scienceboard.net